MA50038A - Anticorps anti-pd-l1 de et son utilisation - Google Patents

Anticorps anti-pd-l1 de et son utilisation

Info

Publication number
MA50038A
MA50038A MA050038A MA50038A MA50038A MA 50038 A MA50038 A MA 50038A MA 050038 A MA050038 A MA 050038A MA 50038 A MA50038 A MA 50038A MA 50038 A MA50038 A MA 50038A
Authority
MA
Morocco
Prior art keywords
antibodies
Prior art date
Application number
MA050038A
Other languages
English (en)
French (fr)
Inventor
Shorena Archuadze
Sergei Barbashov
Vasily Ignatiev
Yan Lavrovsky
Alexey Repik
Mikhail Samsonov
Ting Xu
Original Assignee
R Pharm Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Overseas Inc filed Critical R Pharm Overseas Inc
Publication of MA50038A publication Critical patent/MA50038A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA050038A 2017-04-18 2018-04-18 Anticorps anti-pd-l1 de et son utilisation MA50038A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2017028206 2017-04-18

Publications (1)

Publication Number Publication Date
MA50038A true MA50038A (fr) 2020-07-08

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050038A MA50038A (fr) 2017-04-18 2018-04-18 Anticorps anti-pd-l1 de et son utilisation

Country Status (17)

Country Link
US (1) US20210115143A1 (enExample)
EP (1) EP3612565A4 (enExample)
JP (2) JP2020517239A (enExample)
KR (1) KR102323960B1 (enExample)
CN (1) CN110856446A (enExample)
AU (1) AU2018256392B2 (enExample)
BR (1) BR112019021828B1 (enExample)
CA (1) CA3059447A1 (enExample)
CL (1) CL2019002953A1 (enExample)
CO (1) CO2019012118A2 (enExample)
EA (1) EA201900443A1 (enExample)
MA (1) MA50038A (enExample)
MX (1) MX2019012461A (enExample)
MY (1) MY199319A (enExample)
PH (1) PH12019502302A1 (enExample)
SG (1) SG11201909041SA (enExample)
WO (1) WO2018195226A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7497351B2 (ja) * 2018-11-13 2024-06-10 コンパス セラピューティクス リミテッド ライアビリティ カンパニー チェックポイント分子に対する多重特異性結合性構築物およびその使用
CN113646330A (zh) 2018-11-14 2021-11-12 鲁比克治疗股份有限公司 工程化cd25多肽及其用途
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
CN109929037B (zh) 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
JP7302010B2 (ja) * 2019-04-11 2023-07-03 スクリップス コリア アンチボディ インスティチュート プログラム細胞死タンパク質リガンド－１（ｐｄ－ｌ１）に対する抗体及びその用途
SG11202103000WA (en) * 2019-04-26 2021-04-29 I Mab Biopharma Us Ltd Human pd-l1 antibodies
US20210403568A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
CA3187850A1 (en) 2020-08-04 2022-02-10 Bryan Glaser Pd-l1 binding agents and uses thereof
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
WO2023046113A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US10202454B2 (en) * 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
WO2015103602A1 (en) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
CA3265373A1 (en) * 2014-02-20 2025-10-30 H. Lundbeck A/S Anti-acth antibodies and use thereof
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
MA42971A (fr) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
JP7011657B2 (ja) * 2016-10-30 2022-02-10 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｐｄ－ｌ１抗体および変異型

Also Published As

Publication number Publication date
CO2019012118A2 (es) 2020-04-01
WO2018195226A1 (en) 2018-10-25
CL2019002953A1 (es) 2020-01-10
US20210115143A1 (en) 2021-04-22
EP3612565A1 (en) 2020-02-26
CA3059447A1 (en) 2018-10-25
SG11201909041SA (en) 2019-11-28
JP2023025003A (ja) 2023-02-21
BR112019021828B1 (pt) 2022-09-20
MY199319A (en) 2023-10-24
EA201900443A1 (ru) 2020-03-06
EP3612565A4 (en) 2021-06-16
PH12019502302A1 (en) 2020-09-21
MX2019012461A (es) 2019-12-11
AU2018256392B2 (en) 2024-05-16
BR112019021828A2 (pt) 2020-03-24
KR20190141169A (ko) 2019-12-23
JP2020517239A (ja) 2020-06-18
AU2018256392A1 (en) 2019-10-17
KR102323960B1 (ko) 2021-11-10
CN110856446A (zh) 2020-02-28

Similar Documents

Publication Publication Date Title
EP3904386A4 (en) ANTIBODIES AND USE THEREOF
EP3612565A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
EP3575318A4 (en) ANTI-PD1 ANTIBODIES AND USES THEREOF
EP3802612A4 (en) ANTI-B7-H3 ANTIBODIES AND USE THEREOF
EP3797124A4 (en) ANTI-PD-L1 ANTIBODIES AND USE THEREOF
EP3887403A4 (en) ANTI-4-1BB ANTIBODIES AND USE THEREOF
EP3604338A4 (en) ANTI-OX40 ANTIBODIES AND USES THEREOF
EP3587453A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
EP3907240A4 (en) ANTI-TNFR2 ANTIBODIES AND USE THEREOF
EP3546482A4 (en) ANTI-CD47 ANTIBODIES AND USES THEREOF
EP3626825A4 (en) ANTI-CDH6 ANTIBODIES AND ANTI-CDH6 ANTIBODY INGREDIENT CONJUGATE
EP3599249A4 (en) ANTI-5T4 ANTIBODY MEDICINAL CONJUGATE AND USES THEREOF
EP3572427A4 (en) BCMA TARGETING ANTIBODIES AND USES
EP3523332A4 (en) ANTI-HUMAN 4-1 BB ANTIBODY AND ITS USE
EP3819313A4 (en) BISPECIFIC ANTIBODY AND USE OF IT
EP3400243A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
EP3684812A4 (en) ANTI-CTLA4 ANTIBODIES AND USES THEREOF
MA47311A (fr) Anticorps anti-tgf-bêta et leur utilisation
EP3473649A4 (en) MONOCLONAL ANTI-CD47 ANTIBODIES AND USES THEREOF
EP3589660A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
EP4082570A4 (en) ANTI-CTLA-4 ANTIBODIES AND USE THEREOF
EP3571231A4 (en) ANTI-PD-1 ANTIBODIES AND THEIR USES
EP3363816A4 (en) ANTI-OX40 ANTIBODIES AND USES THEREOF
EP3630844A4 (en) NOVEL ANTI-C-MET ANTIBODY AND USE OF IT